Blocking peptides against HBV: PreS1 protein selected from a phage display library

Biochemical and Biophysical Research Communications

Volumn 412, Issue 4, 2011, Pages 633-637

  Wang, Wei ^a   Liu, Yang ^a   Zu, Xiangyang ^a   Jin, Rui ^a   Xiao, Gengfu ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Blocking; Hepatitis B virus (HBV); Peptide; Phage display; PreS1

Indexed keywords

ANTIVIRUS AGENT; P7 PEPTIDE; PEPTIDE LIBRARY; PRES1 PROTEIN; SINGLE STRANDED DNA; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B VIRUS; NONHUMAN; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ISOLATION; PROTEIN MOTIF; SEQUENCE ALIGNMENT; THERMODYNAMICS; VIRION; VIRUS ASSEMBLY; VIRUS INFECTIVITY;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; OLIGOPEPTIDES; PEPTIDE LIBRARY; PROTEIN PRECURSORS; THERMODYNAMICS;

HEPATITIS B VIRUS;

EID: 80052636174     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.014     Document Type: Article

References (31)

1. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. New England Journal of Medicine 2004, 350:1118-1129.
2. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology 2005, 5:215-229.
3. Wright T.L. Introduction to chronic hepatitis B infection. American Journal of Gastroenterology 2006, 101:S1-6.
4. Cholongitas E., Goulis J., Akriviadis E., Papatheodoridis G.V. Hepatitis B immunoglobulin and/or nucleos(t)ide analog(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transplantation 2011, doi: 10.1002/lt.22354.
5. Viganò M., Lampertico P. Antiviral drugs for HBV liver disease. Expert Opinion on Biological Therapy 2011, 11:285-300.
6. Marcellin P., Asselah T., Boyer N. Treatment of chronic hepatitis B. Journal of Viral Hepatitis 2005, 12:333-345.
7. Deng Q., Zhai J.W., Michel M.L., Zhang J., Qin J., Kong Y.Y., Zhang X.X., Budkowska A., Tiollais P., Wang Y., Xie Y.H. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. Journal of Virology 2007, 81:4244-4254.
8. Bruss V., Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:1059-1063.
9. Bruss V. Hepatitis B virus morphogenesis. World Journal of Gastroenterology 2007, 13:65-73.
10. Petersen J., Dandri M., Mier W., Lütgehetmann M., Volz T., von Weizsäcker F., Haberkorn U., Fischer L., Pollok J.M., Erbes B., Seitz S., Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology 2007, 26:335-341.
11. Gripon P., Le Seyec J., Rumin S., Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 1995, 213:292-299.
12. Le Seyec J., Chouteau P., Cannie I., Guguen-Guillouzo C., Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the preS1 domain. Journal of Virology 1999, 73:2052-2057.
13. Barrera A., Guerra B., Notvall L., Lanford R.E. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. Journal of Virology 2005, 79:9786-9798.
14. Glebe D., Urban S., Knoop E.V., Cag N., Krass P., Grün S., Bulavaite A., Sasnauskas K., Gerlich W.H. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005, 129:234-245.
15. Engelke M., Mills K., Seitz S., Simon P., Gripon P., Schnölzer M., Urban S. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 2006, 43:750-760.
16. Sidhu S.S. Phage display in pharmaceutical biotechnology. Current Opinion in Biotechnology 2000, 11:610-616.
17. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science 1990, 249:386-390.
18. Castel G., Chtéoui M., Heyd B., Tordo N. Phage display of combinatorial peptide libraries: application to antiviral research. Molecules 2011, 16:3499-3518.
19. Parmley S.F., Smith G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988, 73:305-318.
20. Wu K.L., Zhang X., Zhang J., Yang Y., Mu Y.X., Liu M., Lu L., Li Y., Zhu Y., Wu J. Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Research 2005, 112:100-107.
21. Majumdar S., Hajduczki A., Vithayathil R., Olsen T.J., Spitler R.M., Mendez A.S., Thompson T.D., Weiss G.A. In vitro evolution of ligands to the membrane protein caveolin. Journal of the American Chemical Society 2011, 133:9855-9862.
22. Zolotnitsky G., Cogan U., Adir N., Solomon V., Shoham G., Shoham Y. Mapping glycoside hydrolase substrate subsites by isothermal titration calorimetry. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:11275-11280.
23. Wu H.Y., Zhang X.L., Pan Q., Wu J. Functional selection of a type IV pili-binding peptide that specifically inhibits Salmonella Typhi adhesion to/invasion of human monocytic cells. Peptides 2005, 26:2057-2063.
24. Tao J., Xiang J.J., Li D., Deng N., Wang H., Gong Y.P. Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. Biochemical and Biophysical Research Communications 2010, 394:767-773.
25. Zhou X., Kini R.M., Sivaraman J. Application of isothermal titration calorimetry and column chromatography for identification of biomolecular targets. Nature Protocols 2011, 6:158-165.
26. Gripon P., Le S.J., Rumin S., Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 1995, 213:292-299.
27. LeSeyec J., Chouteau P., Cannie I., Guguen-Guillouzo C., Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. Journal of Virology 1999, 73:2052-2057.
28. Barrera A., Guerra B., Notvall L., Lanford R.E. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. Journal of Virology 2005, 79:9786-9798.
29. Glebe D., Urban S., Knoop E.V., Cag N., Krass P., Grun S., Bulavaite A., Sasnauskas K., Gerlich W.H. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005, 129:234-245.
30. Kim D.H., Ni Y., Lee S.H., Urban S., Han K.H. An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus. BMB Reports 2008, 41:640-644.
31. Lowman H.B., Chen Y.M., Skelton N.J., Mortensen D.L., Tomlinson E.E., Sadick M.D., Robinson I.C., Clark R.G. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry 1998, 37:8870-8878.